ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald

https://www.tipranks.com/news/the-fly/heartsciences-recesives-fda-bdd-for-aortic-stenosis-ecg-algorithm-thefly

In This Article:

Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker data for its first program targeting bile acid transporter in Q4 will be an “important catalyst,” the analyst tells investors in a research note. Cantor views the company as a “pure play” on RNA editing.

Protect Your Portfolio Against Market Uncertainty

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on PRQR:

Disclaimer & DisclosureReport an Issue